TG103,Q2W

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	TG103,Q2W
Also known as	TG103 injection, subcutaneous injection,Q2W
Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of TG103 Injection in Type 2 Diabetes Subjects (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TG103,Q2W CI brief — competitive landscape report
TG103,Q2W updates RSS · CI watch RSS
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. portfolio CI